Novo Nordisk's new CEO, Mike Doustdar, who took the helm in August, has signaled a significant shift towards more aggressive acquisitions, particularly in the obesity drug market. This comes as analysts and investors welcome the change, pushing the company to broaden its drug portfolio. Doustdar's predecessor had been more conservative, a stance that led to Novo Nordisk losing out on acquiring Metsera to Pfizer, despite Doustdar making five increasingly costly offers, culminating in an unconventional $10 billion bid.
This new appetite for risk is a direct response to a challenging period for Novo Nordisk, which has lost ground to Eli Lilly in the obesity-drug market. The company is also facing headwinds from upcoming generic competition for semaglutide, the active ingredient in its blockbuster drugs, which will begin to enter the market this year. Additionally, price cuts negotiated with the U.S. government are expected to have a "big impact" on margins, making rapid portfolio expansion a necessity to offset these pressures and drive volume.
Doustdar has publicly stated that Novo Nordisk is "in the market for big or small" deals to bolster its obesity portfolio, showing a willingness to consider substantial investments. This strategic pivot has already created speculative activity in the biotech sector, with companies like Viking Therapeutics seeing their stock rally on takeover rumors. However, the success of this strategy hinges on Novo Nordisk's ability to execute complex acquisitions and the performance of its own pipeline, including the launch of its oral Wegovy, which competes with Eli Lilly's upcoming product.
